BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19931137)

  • 1. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
    Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
    Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
    Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
    Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Papadimitriou CA; Sarris K; Aravantinos G; Kalofonos C; Gika D; Gourgoulis GM; Efstathiou E; Skarlos D; Bafaloukos D
    Gynecol Oncol; 2002 Jun; 85(3):476-82. PubMed ID: 12051877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gass P; Thiel FC; Häberle L; Ackermann S; Theuser AK; Hummel N; Boehm S; Kimmig R; Reinthaller A; Becker S; Hilpert F; Janni W; Vergote I; Harter P; Emons J; Hein A; Beckmann MW; Fasching PA; Pöschke P;
    Gynecol Oncol; 2024 Apr; 183():25-32. PubMed ID: 38490057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
    Kosmas C; Mylonakis N; Tsakonas G; Vorgias G; Karvounis N; Tsavaris N; Daladimos T; Kalinoglou N; Malamos N; Akrivos T; Karabelis A
    Br J Cancer; 2009 Oct; 101(7):1059-65. PubMed ID: 19738606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
    Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
    J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival with bevacizumab in advanced cervical cancer.
    Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
    Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
    Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.
    Viens P; Petit T; Yovine A; Bougnoux P; Deplanque G; Cottu PH; Delva R; Lotz JP; Belle SV; Extra JM; Cvitkovic E
    Ann Oncol; 2006 Mar; 17(3):429-36. PubMed ID: 16500913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for metastatic and recurrent cervical cancer.
    Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
    Zanetta G; Fei F; Parma G; Balestrino M; Lissoni A; Gabriele A; Mangioni C
    Ann Oncol; 1999 Oct; 10(10):1171-4. PubMed ID: 10586332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
    Papadimitriou CA; Sarris K; Moulopoulos LA; Fountzilas G; Anagnostopoulos A; Voulgaris Z; Gika D; Giannakoulis N; Diakomanolis E; Dimopoulos MA
    J Clin Oncol; 1999 Mar; 17(3):761-6. PubMed ID: 10071264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
    Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
    Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
    Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
    J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.